An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

• Published in: AIDS research and therapy Vol. 20; no. 1; p. 17
• Main Authors: Evitt, Lee A, Nanji, Sakina, Grove, Richard A, Okoli, Chinyere, van Wyk, Jean, Snedecor, Sonya J
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 22.03.2023; BioMed Central; BMC
• Subjects: Abacavir; Adverse events; Anti-HIV agents; Anti-HIV Agents - adverse effects; Antiretroviral agents; Antiretroviral therapy; Antiviral agents; Bictegravir; Brief Report; Care and treatment; CD4 antigen; Clinical trials; Comparative analysis; Dolutegravir; Dosage and administration; Drug therapy; Durability; Effectiveness; Emtricitabine; Failure analysis; Hepatitis; Heterocyclic Compounds, 3-Ring - adverse effects; Highly active antiretroviral therapy; HIV; HIV (Viruses); HIV infection; HIV Infections - drug therapy; HIV Integrase Inhibitors - therapeutic use; HIV Seropositivity - drug therapy; HIV-1; HIV-1 infection; Human immunodeficiency virus; Humans; Inhibitors; Integrase; Lamivudine; Lamivudine - adverse effects; Literature reviews; Meta-analysis; Patient outcomes; Reverse transcriptase inhibitors; Risk factors; RNA; Safety; Tablets; Teenagers; Tenofovir; United Kingdom; United States > US; Emtricitabine; HIV-1 infection; Antiretroviral agents; Bictegravir; Lamivudine; Tenofovir alafenamide; Dolutegravir

The long-term efficacy and safety of the 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) and 3-drug single-tablet regimens recommended for antiretroviral therapy (ART)-naive people with HIV-1 (PWH) have yet to be compared directly in clinical trials. This indirect treatment comparison (ITC) was...